Pharmaceutical industry
Seattle Genetics, Inc., a company specializing in the discovery and development of monoclonal antibody-based therapeutics, has formed a strategic collaboration with Bayer Pharmaceuticals Corporation to utilize Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. The ADC technology enables the targeting of specific tumor cells with potent, cell-killing payloads. Under the
Pharmaceutical industry
The merger of Argenta Discovery and Etiologics has created a powerful new firm providing comprehensive drug discovery contract research capabilities to global pharmaceutical customers, while also developing novel agents for respiratory and inflammatory conditions. The newly formed company, Argenta Discovery, employs approximately 120 people and has secured an additional £5.
Pharmaceutical industry
Cambridge Antibody Technology (CATG) announced its financial results for the nine months ended June 30, 2004, and provided an update on its clinical pipeline. The company highlighted several key developments, including the completion of a U.S. clinical trial for its lead proprietary product, Trabio, and the receipt of regulatory
Pharmaceutical industry
Tokyo's stock market experienced an extended downturn in the week leading up to May 17, with the Nikkei 225 index declining 3.5% and closing below the 10,600 level for the first time since February 16, 2004. The Topix index also dropped 2.9%. Investors were anxious
Pharmaceutical industry
The European biotechnology sector, despite witnessing significant investments and advancements in science, faces numerous challenges in bringing its products to market. According to Ernst & Young's 11th annual European Biotechnology report, a dearth of European biotech products has been observed, with only six drug approvals involving European biotechs
Biotechnology industries
Novare Surgical Systems Inc., a pioneer in innovative devices for cardiovascular and vascular surgery, has joined forces with Medtronic Inc., the world's leading medical technology company, to expand the reach of its Enclose II Cardiac Anastomosis Assist Device. This strategic partnership will grant Medtronic's Cardiac Surgery
Biotechnology industries
Invest Northern Ireland, the economic development agency dedicated to attracting foreign investment to Northern Ireland, has chosen CooperKatz & Company as its U.S. marketing/public relations firm. The selection follows a public RFP process where Invest NI evaluated multiple competing companies. CooperKatz will be responsible for designing and executing
Biotechnology industries
Sanofi-SynthElabo SA's hostile bid for Aventis SA gained momentum on Tuesday as the French pharmaceutical group agreed to sell two anti-clotting medications to GlaxoSmithKline plc in anticipation of competition regulators' concerns. The sale of Aritxtra and Fraxiparine to London-based Glaxo, the world's second-largest pharmaceutical company,
Biotechnology industries
Biosurgery, a nascent discipline seeking to revolutionize wound healing and bone repair through the development of engineered tissues and organs, is slowly gaining momentum. Despite the enormous potential of this field, its commercial value is estimated to be 10 to 15 years away. Many companies have already failed or been
Biotechnology industries
Dow AgroSciences, a global leader in providing pest management and biotechnology products, has announced the commercial license acquisition of PureSpiral(TM) technology and the Multi-Left-Border technology from Japan Tobacco Inc. This strategic move enables Dow AgroSciences to enhance its capabilities in improving the efficiency of Agrobacterium-mediated transformation. With a workforce
Biotechnology industries
Norak Biosciences, a private biotechnology company, has entered into a non-exclusive license agreement with the Development Center for Biotechnology (DCB) in Taiwan, granting DCB access to Norak's proprietary Transfluor technology for high-content screening of G protein-coupled receptor (GPCR) targets. This collaboration aims to leverage DCB's state-of-the-art
Biotechnology industries
The French prime minister's public intervention in the proposed takeover of Aventis SA by Swiss pharmaceutical group Novartis AG has sparked fury among French investors, who feel that the government's comments have prejudiced the outcome of the bid. Colette Neuville, the head of shareholder action group
